Navigation Links
Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise
Date:11/14/2011

CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chancejust not as they originally thought.

LateTIME was a study of adult stem cells (autologous) harnessed from bone marrow that were believed to have the ability to improve heart function after an attack if injected into the heart within two weeks of the attack. Results are being released today at American Heart Association Scientific Sessions and published this week in Journal of the American Medical Association (JAMA).

The results have shown the injections within that timeframe were not favorable, but the concept showed great promise, according to an accompanying JAMA editorial that assessed the trial.

The therapy still shows promise for recovering lost or damaged heart tissue resulting from a heart attack. Both UH Case Medical Center's Drs. Dan Simon and Marco Costa, co-investigators in the LateTIME study, are currently participating in a similar trial, "TIME" that already has reduced the time between attack and stem cell injection.

The pair is optimistic the time variable adjustment in the new trial will lend favorable outcomes. Dr. Simon is Chief, Cardiovascular Medicine at UH Case Medical Center and the Herman K. Hellerstein Professor of Cardiovascular Research, Case Western Reserve School of Medicine. Dr. Costa is the director of the Interventional Cardiovascular Center and Research & Innovation Center at UH Case Medical Center as well as a professor of medicine at Case Western Reserve University School of Medicine.

The shared theories in both trials is that the specialized cells could have the ability to promote blood vessel growth, prevent cell death and transform themselves into a number of tissues, including muscle. After an acute heart attack, a remodeling process was initiated in the heart in an attempt to compensate for the damaged areas.

Researchers surmised th
'/>"/>

Contact: Mike Ferrari
mike.ferrari@uhhospitals.org
440-478-4563
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Results triple researchers projections with use of adult stem cells for heart failure
2. Low vitamin C levels may raise heart failure patients risk
3. Diseased hearts to heal themselves in future
4. Biologists use flies and mice to get to the heart of Down syndrome
5. Targeting leg fatigue in heart failure
6. Fatty acids involved in python heart growth could benefit diseased human heart
7. UM School of Medicine finds new pathway critical to heart arrhythmia
8. New study finds fetal heart rate not a good indicator of a babys health
9. Womens heart disease tied to small blood vessels
10. Einstein College of Medicine given $6.7 million to study congenital heart defect genetics
11. WPI mathematics professor Dalin Tang elected a Fellow of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... during the Oligocene epoch, some 33.6 million years ago, ... the Andalusian Institute of Earth Sciences (IACT)a Spanish National ... on information contained in ice sediments from different depths, ... ., Before the ice covered Antarctica, the Earth was ...
... a world-leading provider of scientific, technical and medical ... the launch of Translational Proteomics , an ... discoveries in the field of proteomics to clinical ... Jean-Charles Sanchez, Associate Professor at the University ...
... at UC Irvine reported this week that a synthetic compound ... found to enhance metabolic activity and shows potential as a ... published the week of May 27 in the Proceedings ... selectively blocks the activity of a protein that promotes inflammation ...
Cached Biology News:The Antarctic polar icecap is 33.6 million years old 2UCI researchers find sea anemone venom-derived compound effective in anti-obesity studies 2UCI researchers find sea anemone venom-derived compound effective in anti-obesity studies 3
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Network,s 3-Minute,Press Show is a daily program hosted by ... company executives on their,company and most recent press releases., ... insight into a company,s,latest news, and its impact on ... Monday through Friday at: http://tv.wallst.net/3-min-press/3-min-press.php , ...
... Gaining a first-cycle,approval for a new molecular ... incremental revenue on average, according to a new ... International (Nasdaq: PRXL ),and leading global life ... According to the PAREXEL Consulting,analysis, 60 percent of ...
... DC The future of how the world ... likely come from the same source: nanotechnology. According ... the Project on Emerging Nanotechnologies (PEN), nanotechnology will ... electronics and "green" energy technologies. , In ...
Cached Biology Technology:[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5
Mouse Cell Line Slides...
Request Info...
Human Cell Line Slides...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
Biology Products: